Ace angioedema
Pro Research Analysisby 
Searched over 200M research papers for "ace angioedema"
ACE Inhibitor-Induced Angioedema: Incidence, Pathophysiology, and Treatment
Incidence and Risk Factors of ACE Inhibitor-Induced Angioedema
Angiotensin-converting enzyme (ACE) inhibitor-induced angioedema is a rare but potentially life-threatening adverse effect, occurring in approximately 0.1% to 0.7% of patients treated with ACE inhibitors 124. The incidence is notably higher among certain populations, including African Americans, Hispanics, smokers, women, older individuals, and those with a history of drug rash or seasonal allergies 24. The risk is also elevated in patients using immunosuppressive therapy or other medications that affect the renin-angiotensin system .
Pathophysiology of ACE Inhibitor-Induced Angioedema
The pathogenesis of ACE inhibitor-induced angioedema primarily involves the accumulation of bradykinin, a peptide that causes vasodilation and increased vascular permeability 124. ACE inhibitors prevent the breakdown of bradykinin, leading to its accumulation and subsequent angioedema. Other mediators such as histamine, substance P, and prostaglandins may also play a role, although their exact contributions are not fully understood 14. Genetic factors, including polymorphisms in genes related to bradykinin metabolism, have been suggested to contribute to the susceptibility to this condition 2910.
Clinical Manifestations
ACE inhibitor-induced angioedema typically presents with swelling of the face, lips, tongue, uvula, and upper airways, which can lead to airway obstruction and necessitate emergency interventions such as intubation or tracheotomy 23. In some cases, intestinal involvement with sub-occlusive symptoms has been reported . The onset of symptoms can occur within hours to years after starting ACE inhibitor therapy, making it a challenging condition to predict and diagnose 17.
Treatment and Management
Immediate withdrawal of the ACE inhibitor is crucial upon the onset of angioedema 14. Standard treatments include supportive care, corticosteroids, antihistamines, and epinephrine, although their efficacy is limited 24. Icatibant, a selective bradykinin B2 receptor antagonist, has shown promise in reducing the time to resolution of symptoms compared to standard therapy with glucocorticoids and antihistamines . However, its efficacy may vary among different ethnic groups, with some studies indicating less effectiveness in Black patients 29.
Recurrence and Alternative Therapies
Patients who experience ACE inhibitor-induced angioedema are at risk of recurrence if re-exposed to ACE inhibitors and should avoid this class of drugs permanently . Angiotensin receptor blockers (ARBs) are often considered as an alternative; however, there is a small risk of angioedema recurrence with ARBs, estimated between 2% and 17% 28. The incidence of angioedema with ARBs and direct renin inhibitors (DRIs) is significantly lower than with ACE inhibitors and is comparable to placebo .
Conclusion
ACE inhibitor-induced angioedema is a rare but serious condition that requires prompt recognition and management. Understanding the risk factors, pathophysiology, and effective treatment options is essential for minimizing the impact of this adverse effect. While icatibant offers a promising treatment, further research is needed to confirm its efficacy across different populations. Avoidance of ACE inhibitors in high-risk individuals and careful monitoring of alternative therapies are crucial steps in managing this condition.
Sources and full results
Most relevant research papers on this topic
A randomized trial of icatibant in ACE-inhibitor-induced angioedema.
Icatibant significantly shorterens the time to complete resolution of edema in patients with ACE-inhibitor-induced angioedema compared to standard therapy with glucocorticoid and antihistamine.
ACE Inhibitor-Induced Angioedema: a Review
ACE inhibitors are frequently used but associated with angioedema, which should be avoided in high-risk individuals and treated with early diagnosis, tracheal intubation, and avoidance of re-challenge.
Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors.
Angioedema risk is higher with ACE inhibitors than with ARBs and DRIs, and is higher in heart failure patients compared to those without heart failure.
Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy
Cough occurs in 5% to 20% of ACE inhibitor patients and angioedema occurs in 0.1% to 0.2%, with treatment involving airway protection, antihistamines, and corticosteroids.
Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis.
The risk of developing angioedema after taking an ACE-I and an ARB is between 2% and 17%, with a 0% to 9.2% risk for confirmed angioedema.
DOI